NCT00918398

AZD1981 Bioavailability Study of Intravenous (IV) and Oral Formulations

An Open, Single-dose, Phase I, 4-period Partly Crossover Study in Healthy Men or Women to Assess Relative Bioavailability of Oral Administration of AZD1981 Via Tablets Compared With Suspension and Basic Systemic Pharmacokinetic Parameters After Intravenous Administration

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 14 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The primary objective is to investigate the pharmacokinetics of AZD1981 given in different formulations and to measure renal clearance

Conditions

• Healthy
• Postmenopausal
• Surgically Sterile Women

Interventions

Type	Name	Description
DRUG	AZD1981	100 mg iv infusion, single dose, 4 hours infusion
DRUG	AZD1981	514 mg oral solution, single dose
DRUG	AZD1981	500 mg oral tablet A (optimal dissolution) give as 2x250 mg tablets, single dose
DRUG	AZD1981	500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose

Timeline

• Start date: 2009-06-01
• Completion: 2009-07-01
• First posted: 2009-06-11
• Last updated: 2009-07-30

Locations

1 site across 1 country: Sweden